Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 3—March 2018
Research

Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000–2015

Miranda G. LoutetComments to Author , Jennifer A. Davidson, Tim Brown, Martin Dedicoat, H. Lucy Thomas, and Maeve K. Lalor
Author affiliations: Public Health England, London, UK (M.G. Loutet, J.A. Davidson, T. Brown, H.L. Thomas, M.K. Lalor); Heart of England NHS Foundation Trust, Birmingham, UK (M. Dedicoat); University College London, London (M.K. Lalor)

Main Article

Table 5

Univariable and multivariable logistic regression model 1 for acquired resistance to ant-TB drugs in England, Wales, and Northern Ireland, 2000–2015*

Characteristic No acquired drug resistance, no. (%) Acquired drug resistance, no. (%) Univariable analysis
Multivariable analysis
OR (95% CI) p value OR (95% CI) p value
Age, y
0–14 1,391 (2.1) 2 (1.3) 1.0 NA NA NA
15–44 44,227 (65.5) 111 (70.3) 1.7 (0.4–7.1) 0.4 1.6 (0.4–6.7) 0.5
45–64 12,859 (19.0) 40 (25.3) 2.2 (0.5–9.0) 0.3 2.5 (0.6–10.7) 0.2
>65
9,071 (13.4)
5 (3.2)
0.4 (0.1–2.0)
0.2

0.6 (0.1–3.2)
0.5
Sex
F 28,453 (42.2) 64 (40.5) 1.0 NA NA NA
M
38,985 (57.8)
94 (59.5)
1.1 (0.8–1.5)
0.7

1.2 (0.8–1.6)
0.4
Site of disease
Extrapulmonary only 24,217 (35.9) 27 (17.1) 1.0 NA NA NA
Pulmonary with or without 
extrapulmonary
43,313 (64.1)
131 (82.9)
2.7 (1.8–4.1)
<0.001

2.1 (1.3–3.3)
0.003
Initial drug resistance
Drug sensitive 62,721 (92.9) 74 (46.8) 1.0 NA NA NA
Isoniazid resistance 
without MDR 3,830 (5.7) 34 (21.5) 7.5 (5.0–11.3) <0.001 6.2 (3.9–10.0) <0.001
Rifampin resistance 
without MDR 200 (0.3) 3 (1.9) 12.7 (4.0–40.7) <0.001 10.8 (3.3–35.3) <0.001
MDR
801 (1.2)
47 (29.7)
49.7 (34.3–72.2)
<0.001

41.8 (27.0–64.7)
<0.001
Country of birth
United Kingdom 16,184 (26.3) 38 (25.7) 1.0 NA NA NA
China 465 (0.8) 6 (4.1) 5.5 (2.3–13.1) <0.001 3.4 (1.3–8.8) 0.01
India 11,227 1(8.3) 11 (7.4) 0.4 (0.2–0.8) 0.01 0.4 (0.2–0.8) 0.01
Lithuania 238 (0.4) 9 (6.1) 16.1 (7.7–33.7) <0.001 1.8 (0.8–4.4) 0.2
Pakistan 7,696 (12.5) 15 (10.1) 0.8 (0.5–1.5) 0.6 0.9 (0.4–1.7) 0.6
Somalia 4,184 (6.8) 9 (6.1) 0.9 (0.4–1.9) 0.9 0.9 (0.4–1.9) 0.7
South Africa 759 (1.2) 5 (3.4) 2.8 (1.1–7.1) 0.03 2.8 (1.1–7.5) 0.04
Nigeria 1,324 (2.2) 4 (2.7) 1.3 (0.5–3.6) 0.6 0.8 (0.2–2.6) 0.7
Other
19,417 (31.6)
51 (34.5)
1.1 (0.7–1.7)
0.6

0.9 (0.6–1.5)
0.8
Previous TB episode
No 54,346 (93.3) 109 (77.3) 1.0 NA NA NA
Yes 3,910 (6.7) 32 (22.7) 4.0 (2.7–6.1) <0.001 2.3 (1.5–3.5) <0.001

*MDR, multidrug-resistant; NA, not applicable; OR, odds ratio; TB, tuberculosis.

Main Article

Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external